132 related articles for article (PubMed ID: 34233076)
1. Design, synthesis, and primary activity assays of baicalein derivatives as cyclin-dependent kinase 1 inhibitors.
Mou J; Qiu S; Chen D; Deng Y; Tekleab T
Chem Biol Drug Des; 2021 Oct; 98(4):639-654. PubMed ID: 34233076
[TBL] [Abstract][Full Text] [Related]
2. Design of new disubstituted imidazo[1,2-
Elie J; Feizbakhsh O; Desban N; Josselin B; Baratte B; Bescond A; Duez J; Fant X; Bach S; Marie D; Place M; Ben Salah S; Chartier A; Berteina-Raboin S; Chaikuad A; Knapp S; Carles F; Bonnet P; Buron F; Routier S; Ruchaud S
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1840-1853. PubMed ID: 33040634
[TBL] [Abstract][Full Text] [Related]
3. Nitrogen-containing flavonoids as CDK1/Cyclin B inhibitors: design, synthesis, and biological evaluation.
Liu T; Xu Z; He Q; Chen Y; Yang B; Hu Y
Bioorg Med Chem Lett; 2007 Jan; 17(1):278-81. PubMed ID: 17085048
[TBL] [Abstract][Full Text] [Related]
4. Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT.
Chao JI; Su WC; Liu HF
Mol Cancer Ther; 2007 Nov; 6(11):3039-48. PubMed ID: 18025287
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a class of diheteroaromatic amines as orally bioavailable CDK1/4/6 inhibitors.
Fu Y; Tang S; Su Y; Lan X; Ye Y; Zha C; Li L; Cao J; Chen Y; Jiang L; Huang Y; Ding J; Geng M; Huang M; Wan H
Bioorg Med Chem Lett; 2017 Dec; 27(23):5332-5336. PubMed ID: 29074254
[TBL] [Abstract][Full Text] [Related]
6. A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells.
Pecoraro C; Parrino B; Cascioferro S; Puerta A; Avan A; Peters GJ; Diana P; Giovannetti E; Carbone D
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011251
[TBL] [Abstract][Full Text] [Related]
7. Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
El-Naggar AM; El-Hashash MA; Elkaeed EB
Bioorg Chem; 2021 Mar; 108():104615. PubMed ID: 33484942
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole-Indole Conjugates as Anticancer CDK Inhibitors.
Al-Warhi T; El Kerdawy AM; Aljaeed N; Ismael OE; Ayyad RR; Eldehna WM; Abdel-Aziz HA; Al-Ansary GH
Molecules; 2020 Apr; 25(9):. PubMed ID: 32349307
[TBL] [Abstract][Full Text] [Related]
9. Identification of a new series of flavopiridol-like structures as kinase inhibitors with high cytotoxic potency.
Ibrahim N; Bonnet P; Brion JD; Peyrat JF; Bignon J; Levaique H; Josselin B; Robert T; Colas P; Bach S; Messaoudi S; Alami M; Hamze A
Eur J Med Chem; 2020 Aug; 199():112355. PubMed ID: 32402934
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Activity Assays of Cyclin-Dependent Kinase 1 Inhibitors With Flavone Scaffolds.
Fu L; Mou J; Deng Y; Ren X; Qiu S
Front Chem; 2022; 10():940427. PubMed ID: 36003621
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of guanidino analogues of roscovitine.
Dolečková I; Cesnek M; Dračinský M; Brynda J; Voller J; Janeba Z; Kryštof V
Eur J Med Chem; 2013 Apr; 62():443-52. PubMed ID: 23399722
[TBL] [Abstract][Full Text] [Related]
12. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity.
Schultz C; Link A; Leost M; Zaharevitz DW; Gussio R; Sausville EA; Meijer L; Kunick C
J Med Chem; 1999 Jul; 42(15):2909-19. PubMed ID: 10425100
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
14. Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening.
Elkamhawy A; Ammar UM; Paik S; Abdellattif MH; Elsherbeny MH; Lee K; Roh EJ
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500757
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-1,3-diphenyl-1H-pyrazole-4-carboxamides as CDK1/Cdc2 inhibitors.
Ganga Reddy V; Srinivasa Reddy T; Lakshma Nayak V; Prasad B; Reddy AP; Ravikumar A; Taj S; Kamal A
Eur J Med Chem; 2016 Oct; 122():164-177. PubMed ID: 27344493
[TBL] [Abstract][Full Text] [Related]
16. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.
Kim KS; Sack JS; Tokarski JS; Qian L; Chao ST; Leith L; Kelly YF; Misra RN; Hunt JT; Kimball SD; Humphreys WG; Wautlet BS; Mulheron JG; Webster KR
J Med Chem; 2000 Nov; 43(22):4126-34. PubMed ID: 11063609
[TBL] [Abstract][Full Text] [Related]
17. Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.
Wang J; Li T; Zhao T; Wu T; Liu C; Ding H; Li Z; Bian J
Eur J Med Chem; 2019 Sep; 178():782-801. PubMed ID: 31238183
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
Mou J; Chen D; Deng Y
Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
[TBL] [Abstract][Full Text] [Related]
19. Homology modeling, molecular dynamic simulation and docking studies of cyclin dependent kinase 1.
Zhang L; Zhu H; Wang Q; Fang H; Xu W; Li M
J Mol Model; 2011 Feb; 17(2):219-26. PubMed ID: 20419498
[TBL] [Abstract][Full Text] [Related]
20. Molecular models of cyclin-dependent kinase 1 complexed with inhibitors.
Canduri F; Uchoa HB; de Azevedo WF
Biochem Biophys Res Commun; 2004 Nov; 324(2):661-6. PubMed ID: 15474478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
